SCHEMBL5543513

SCHEMBL5543513

FC(F)(F)C(F)(F)Oc1ccccc1CNc1cc[c]cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
HTT P42858 4/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 7/20 0.40
GAA P10253 6/20 0.40
THRB P10828 5/20 0.40
ALDH1A1 P00352 4/20 0.40
BLM P54132 3/20 0.40
KDM4E B2RXH2 3/20 0.40
TP53 P04637 3/20 0.40
ESR1 P03372 1/20 0.40
PKM P14618 1/20 0.40
ALOX12 P18054 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ESR2 Q92731 1/20 0.40
TDP1 Q9NUW8 4/20 0.40
RECQL P46063 1/20 0.40
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5535891 0.88 MAPT (0.50) MAPTMEN1KMT2AHTTRAB9A
SCHEMBL5544051 0.87 MEN1 (0.33) MAPTMEN1KMT2AHTTRAB9A
SCHEMBL5535825 0.85 MAPT (0.34) MAPTMEN1KMT2AHTTRAB9A
SCHEMBL5545445 0.75 SLC6A3 (0.40) MAPTMEN1KMT2AHTTRAB9A
SCHEMBL5534664 0.75 MAPT (0.37) MAPTMEN1KMT2ARAB9AL3MBTL1
SCHEMBL5537594 0.75 MAPT (0.38) MAPTMEN1KMT2AHTTRAB9A
SCHEMBL5543537 0.74 L3MBTL1 (0.44) MAPTMEN1KMT2AHTTRAB9A
SCHEMBL5545152 0.74 HDAC3 (0.45) MAPTMEN1KMT2AHTTRAB9A
SCHEMBL5536443 0.74 HDAC1 (0.41) MAPTMEN1KMT2AHTTRAB9A
SCHEMBL5540283 0.73 DRD2 (0.38) MAPTMEN1KMT2AHTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885MEN1 3295/4885KMT2A 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.